Zelboraf (vemurafenib), manufactured by Roche, has been approved by the European Commission, for treating patients with BRAF V600 mutation-positive metastatic melanoma, a deadly, and dangerous type of skin cancer. Zelboraf works by seeking out the mutated parts of the BRAF protein, found in about 50% of all melanoma cases, and blocking its action. Hal Barron, M.D., head of Global Product Development and Chief Medical Officer at Roche said: "Today's approval is important news for people with BRAF mutation-positive metastatic melanoma as Zelborad significantly improves patient survival and exemplifies the benefits that Roche's personalized approach to medicine can provide for patients, physicians, and society." The Roche cobs 4800 BRAF V600 Mutation Test, a diagnostic test co-designed by Roche, to figure out which patients were eligible for treatment, showed that Zelboraf is the only known treatment which benefits the survival rates in some patients with accelerated melanoma who possess the BRAF V600 mutation, and who have been treated before or have not previously been treated.
Scabies is a contagious skin condition caused by tiny mites called Sarcoptes scabiei. These mites burrow into the skin, then breed and lay their eggs, causing a rash and intense itchiness. Sufferers of scabies rarely know they have the condition until a number of weeks after initial infection; this means scabies infestations can spread quickly. Scabies is commonly seen as a condition brought about by poor living conditions and lack of personal hygiene, but there is no evidence that suggests this to be true. Scabies can affect anyone and can be treated with certain creams and lotions. There are some groups however that are at greater risk of having the condition. According to Medilexicon's medical dictionary, scabies is: 1. An eruption due to the mite Sarcoptes scabiei var. hominis; the female of the species burrows into the skin, producing a vesicular eruption with intense pruritus between the fingers, on the male or female genitalia, buttocks, and elsewhere on the trunk and extremities.
A recent study conducted by the U.S Food And Drug Administration (FDA) reveals that over 400 popular lipstick brands contain twice as much lead as previously believed - up to 7.19 parts per million (ppm). Mark Mitchell, M.D., MPH, policy advisor of the Connecticut Coalition for Environmental Justice and co-chair of the Environmental Health Task Force for the National Medical Association comments: "Lead builds up in the body over time and lead-containing lipstick applied several times a day, every day, can add up to significant exposure levels." Maybelline Color Sensation, by L'Oreal USA, was found to have the most lead of all the brands that the FDA tested, with 275 times more than the brand with the lowest amount of lead - Wet & Wild Mega Mixers Lip Balm. The Wet & Wild lip balm happened to be the least expensive, which shows that a high-priced lipstick does not mean it is safe.
One of the first large-scale genomic studies conducted in a developing country has discovered genetic variants that elevate the risk for skin lesions in people chronically exposed to arsenic. Genetic changes found near the enzyme for metabolizing the chemical into a less toxic form can significantly increase an individual's risk for developing arsenic-related disease. The discovery could point the way to new screening and intervention options for people who are exposed to groundwater with high levels of arsenic, said scientists at the University of Chicago Medicine, Columbia University, and in Bangladesh in a study published in PLoS Genetics. "These results add clarity to the genetic architecture that is playing a role in arsenic toxicity and its underlying biology, " said senior author Habibul Ahsan, MD, MMedSc, Louis Block Professor of health studies, medicine and human genetics at the University of Chicago Medicine.
PLoS Genetics reports that a large-scale genomic study in Bangladesh has found genetic variants that control arsenic metabolism and increase the risk of skin lesions in people chronically exposed to arsenic. The genetic variants that were found near the enzyme for metabolizing the chemical into a less toxic form are linked to the risk of developing arsenic-related disease according to the researchers from the University of Chicago, Columbia University, the International Center for Diarrheal Disease Research in Bangladesh, and the University of North Carolina. Since the 1970s, when hand-pumped wells to access groundwater sources were installed, as many as 77 million people representing around half of Bangladesh's population, have been accidentally exposed to dangerous levels of arsenic.